Roots Analysis has announced the addition of “Fc Fusion Therapeutics Market, 2021-2030” report to its list of offerings.
With 13 drugs approved in the European Union and the US, Fc fusion therapeutics are considered to be one of the most successful classes of IgG-based products. The success of these biopharmaceutical products can be attributed to their diverse biological and pharmacological properties, including an extended serum half-life, enhanced Fc mediated effector functions, easy expression, increased stability and aggregation resistance, modulated immunogenicity and improved safety profiles, for the treatment of a wide range of disease indications
To order this 130+ page report, which features 95+ figures and 140+ tables, please visit
https://www.rootsanalysis.com/reports/fc-fusion-therapeutics-market.html
Key Market Insights
Presently, more than 115 Fc fusion therapeutics are approved / under development
Over 60% of the aforementioned candidates are being evaluated in clinical stages; of these, 50 molecules are in advanced phases (Phase II and above) of clinical trials. This is followed by more than 30% of the Fc fusion therapeutics which are already marketed for various disease indications. It is worth noting that majority of the pipeline therapies (18) are being developed to target PD-L1 for the treatment of oncological disorders.
More than 25 companies claim to be engaged in the development of Fc fusion therapeutics
Post 2001, there has been a significant rise in the number of companies working in this domain. It is worth noting that majority (48%) of the firms engaged in this domain are based in North America, followed by those headquartered in Asia-Pacific (38%) and Europe (3%).
To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/fc-fusion-therapeutics-market/request-sample.html
For additional details, please visit
https://www.rootsanalysis.com/reports/fc-fusion-therapeutics-market.html
or email [email protected]
You may also be interested in the following titles:
1. Regulatory T-Cell Therapies (Tregs) Market, 2021–2035
2. CD47 Targeting Therapeutics Market, 2021-2035
3. Light Activated Therapies Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the fc fusion protein for haemophilia market include Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan, AOSAIKANG Pharma, Luoxin Pharma, LIVZON, and Eastchina Pharma.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Fc Fusion Protein for Haemophilia Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/fc-fusion-protein-for-haemophilia-market/download-sampleMarket DynamicsFc fusion protein is broadly preferred for haemophilia treatment.
The prevalence varies with the reporting country, with a range of 5.4-14.5 cases per 100,000 males.
Hemophilia B occurs in around 1 in 25,000 male births, which is less prevalent than hemophilia A.
Improving treatment services, growing awareness about the syndrome, rising life expectancy, and easy access to treatment favor market growth too much extent.
